Articles related to SCHIZOPHRENIA

Explore the latest research on non-dopaminergic mechanisms for schizophrenia treatment, revealing innovative approaches that may lead to more effective and well-tolerated therapies.

The latest systematic review on olanzapine for schizophrenia treatment has defined a therapeutic reference range of 20-40 ng/mL, offering insight into optimal efficacy and tolerable levels. Explore the full study to understand how these findings can inform clinical practice and patient care.

Explore the complexities of recently found pathomechanisms, cutting-edge research on emergent molecular pathways, and thorough insights into novel treatment options.

This groundbreaking study from Northwestern Medicine unveils a surprising interaction of antipsychotic drugs with neurons, prompting a revision of our understanding of psychosis treatment and opening new pathways for more effective, safer drugs.

NEW YORK CITY | THE GLASSHOUSE CHELSEASATURDAY, JUNE 24, 2023 In a comprehensive in-person setting, psychiatrists will get current, clinically relevant, and practice-based updates. This full-day conference will feature interesting presentations conducted by renowned thought leaders in schizophrenia, postpartum depression, major depressive disorder, ADHD, and addiction. Each session will include a patient perspective to ensure professionals obtain practical, real-world understanding.

Poor adherence to treatment is the biggest predictor in relapse in serious mental illnesses. In this 0.5-CME credit activity, the panel discusses key contributors to the adherence challenge and strategies for improving adherence – including use of newer, better tolerated therapies. Available in video, podcast, and text.